高龄患者腹主动脉瘤腔内修复术的疗效分析
生存获益主要限于Gagne指数0-1且AAA≥5.5cm或Gagne指数2-5且AAA≥7.0cm的患者,需谨慎选择。
要点
- 高龄患者EVAR后实际1年死亡率低于预测未手术死亡率。
- AAA<5.5cm者EVAR后1年死亡率反而更差。
- Gagne指数0-1者AAA>5.5cm即可获益,2-5者需≥7.0cm。
核心结论
- EVAR可降低高龄患者1年死亡率,但生存获益主要限于低合并症且动脉瘤较大者。
主要发现
- 预测未手术1年死亡率为11.9%,实际EVAR后为8.2%(p<0.001)。
- 围术期主要不良心血管事件(MACE)发生率为4.4%(n=516)。
- AAA<5.5cm者EVAR后实际1年死亡率劣于预测未手术死亡率;AAA≥5.5cm者则更优。
- Gagne指数2-5者获益主要限于AAA≥7.0cm;Gagne指数0-1者AAA>5.5cm即获益。
关键数值与推荐
- 最大AAA直径分布:<5.5cm占39.6%,5.5-5.9cm占28.6%,6.0-6.9cm占21.3%,≥7.0cm占10.6%。
- 中位年龄84岁[81,86],男性占76.2%。
临床怎么用
- 对高龄AAA患者,应结合动脉瘤直径和Gagne指数选择EVAR,避免对低获益人群过度干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Treatment decisions for the elderly with abdominal aortic aneurysms (AAAs) are challenging. With advancing age, the risk of endovascular aneurysm repair (EVAR) increases while life expectancy decreases, which may nullify the benefit of EVAR. The purpose of this study was to quantify the impact of EVAR on 1-year mortality in patients of advanced age. MATERIALS AND METHODS: The 2003-2020 Vascular Quality Initiative Database was utilized to identify patients who underwent EVAR for AAAs. Patients were included if they were 80 years of age or older. Exclusions included non-elective surgery or missing aortic diameter data. Predicted 1-year mortality of untreated AAAs was calculated based on a validated comorbidity score that predicts 1-year mortality (Gagne Index, excluding the component associated with AAAs) plus the 1-year aneurysm-related mortality without repair. The primary outcome for the study was 1-year mortality. RESULTS: A total of 11 829 patients met study criteria. The median age was 84 years [81, 86] with 9014 (76.2%) being male. Maximal AAA diameters were apportioned as follows: 39.6% were <5.5 cm, 28.6% were 5.5-5.9 cm, 21.3% were 6.0-6.9 cm, and 10.6% were ≥7.0 cm. The predicted 1-year mortality rate without EVAR was 11.9%, which was significantly higher than the actual 1-year mortality rate with EVAR (8.2%; p<0.001). The overall rate of perioperative MACE was 4.4% (n = 516). Patients with an aneurysm diameter <5.5cm had worse actual 1-year mortality rates with EVAR compared to predicted 1-year mortality rates without EVAR. In contrast, those with larger aneurysms (≥5.5cm) had better actual 1-year mortality rates with EVAR. The benefit from EVAR for those with Gagne Indices 2-5 was largely restricted to those with AAAs ≥ 7.0cm; whereas those with Gagne Indices 0-1 experience a survival benefit for AAAs larger than 5.5 cm. CONCLUSION: The current data suggest that EVAR decreases 1-year mortality rates for patients of advanced age compared to non-operative management in the elderly. However, the survival benefit is largely limited to those with Gagne Indices 0-1 with AAAs ≥ 5.5 cm and Gagne Indices 2-5 with AAAs ≥ 7.0 cm. Those of advanced age may benefit from EVAR, but realizing this benefit requires careful patient selection.
引用
- Khoury MK, Thornton MA, Heid CA, et al. Endovascular Aortic Repair in Patients of Advanced Age. J Endovasc Ther. 2021. PMID: 34622707. doi:10.1177/15266028211049342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。